The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
16-Oct-15
$2.1 billion
Target:
Stemcor Holdings Limited
Advised Stemcor Holdings Limited, the global steel trader, on their restructuring of $1.0bn of senior and junior debt and the refinancing of a $1.1bn working capital facility
14-Oct-15
$330 million
Target:
Professional Service Industries, Inc.
Acquiror:
Intertek Group plc
Advised Intertek Group plc, a leading quality solutions provider to industries worldwide, on its $330 million acquisition of Professional Service Industries, Inc. (“PSI”), a leading US based provider of testing and assurance services to commercial and civil construction markets
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
04-Jun-15
$1.5 billion
Target:
Moorebank Intermodal Terminal Project
Acquiror:
Qube / Aurizon
Advised the Australian Government on the public-private partnership with a consortium comprising Qube (ASX: QUB) and Aurizon (ASX:AZJ) to develop and operate a A$1.9 billion import /export and interstate intermodal terminal as well as associated warehousing and rail infrastructure in Moorebank, Sydney
02-Jun-15
$NA
Target:
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Acquiror:
Perrigo Company plc
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
21-Apr-15
$963 million
Target:
Refinancing of syndicated bank debt facilities
Acquiror:
Primary Health Care
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
30-Mar-15
$950 million
Target:
Quindell plc’s Professional Services Division
Acquiror:
Slater and Gordon
Advised Slater and Gordon Limited, an ASX-listed international consumer law firm, on the acquisition of Quindell plc’s Professional Services Division, the UK’s leading personal injury law firm operating across the claims value chain, and associated A$890 million equity and A$375 million debt raisings
24-Feb-15
$NA
Target:
Azelis Group (majority owned by 3i)
Acquiror:
Funds advised by Apax Partners
Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners
19-Feb-15
$8.4 billion
Target:
Rexam plc
Acquiror:
Ball Corporation
Advised Ball Corporation, a leading manufacturer of metal packaging products for the global beverage, food, personal care and household products industries as well as a provider of systems and technologies for the aerospace industry, on the acquisition of Rexam plc, a leading beverage can manufacturer
29-Jan-15
$44 million
Target:
Airnorth
Acquiror:
Bristow Group
Advised Airnorth, Australia’s largest independent Airline, on the sale of 85% of its shares on issue to Bristow Group, a leading provider of helicopter services to the worldwide offshore energy industry, for an implied 100% equity value of US$44m
22-Jan-15
$NA
Target:
Hitachi Appliances, Inc.
Acquiror:
Johnson Controls
Advised Hitachi, LTD / Hitachi Appliances, Inc, a leading global industrial conglomerate focused on information and telecommunications systems, power systems and social systems, on their formation of a global HVAC joint venture with Johnson Controls
23-Oct-14
$NA
Target:
Boart Longyear Ltd.
Advised the Board of Directors of Boart Longyear, the world’s leading supplier of drilling services and equipment for mining and drilling companies, on its strategic review process and subsequent comprehensive recapitalization transactions with certain affiliates of Centerbridge Partners, L.P.
22-Oct-14
$112 million
Target:
Nuplex Industries’ Specialties and Masterbatch businesses
Acquiror:
CHAMP Private Equity
Advised Nuplex Industries, a dual listed (ASX/NZX) global manufacturer, developer and distributor of resins and additives, on the sale of its specialty chemicals and masterbatch businesses to CHAMP Private Equity, a leading Australian private equity firm
09-Sep-14
$NA
Target:
Atwood Mobile Products, LLC
Acquiror:
Dometic Group AB
Advised Dometic Group AB, a portfolio company of EQT, on its acquisition of Atwood Mobile Products, a global manufacturer of appliances and hardware for the RV, On-/Off-Highway and Marine industries
28-Jul-14
$90 million
Target:
Clinuvel Pharmaceuticals Limited
Acquiror:
Retrophin, Inc.
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
26-Jun-14
$2.9 billion
Target:
Firth Rixson Limited
Acquiror:
Alcoa Inc.
Advised Alcoa Inc. on the acquisition of Firth Rixson Limited, a leading provider of highly engineered rings, industrial forgings and specialized metal products primarily to the aerospace industry
26-Jun-14
$2.7 billion
Target:
Frank Russell Company
Acquiror:
London Stock Exchange Group plc
Advised LSEG on the proposed acquisition of Frank Russell Company, the number one provider of benchmarks to US-focused equity funds and a leading provider of multi-asset class investment solutions, from Northwestern Mutual Life Insurance Company, including acting as Joint Sponsor to LSEG on its $1.6 billion rights issue
11-Apr-14
$414 million
Target:
Investec Bank (Australia) Limited
Acquiror:
Bank of Queensland Limited
Advised Investec Bank (Australia) Limited on the sale of its Professional Finance and Asset Finance and Leasing businesses, its deposit book, and its Australian banking licence to Bank of Queensland Limited (“BOQ”). BOQ is a leading regional Australian bank which provides retail and business banking
05-Feb-14
$NA
Target:
Unfors Raysafe AB
Acquiror:
Fluke Biomedical Corporation
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
09-Sep-13
$1.2 billion
Target:
Sinclair Knight Merz
Acquiror:
Jacobs Engineering Group
Advised Sinclair Knight Merz, a leading projects firm, with global capability in strategic consulting, engineering and project delivery on its recommended merger with Jacobs Engineering
01-Aug-13
$62 million
Target:
Futuris Automotive
Acquiror:
Clearlake Capital
Advised Elders on the sale of Futuris Automotive, Australia’s largest automotive component manufacturer, to Clearlake Capital, a US based private equity firm
31-Jul-13
$NA
Target:
CPP Group plc
Advised on the comprehensive restructuring of its balance sheet, including sale of the US business, terming out the existing RCF and creation of additional liquidity by the long term deferral of business partner payments
12-Jun-13
$893 million
Target:
A$1.6bn non-core loan portfolio
Acquiror:
Goldman Sachs Group. Inc.
Advised Suncorp Group Ltd (ASX:SUN), a leading general insurance, retail banking and life insurance group in Australia and New Zealand, on the sale of a A$1.6bn portfolio of performing and non-performing (corporate and property) loans to Goldman Sachs Group Inc., an American multinational investment banking firm
31-May-13
$57 million
Target:
d-cyphaTrade Limited
Acquiror:
Australian Securities Exchange (ASX)
Advised Transpower New Zealand, the state owned owner-operator of New Zealand’s electricity distribution network on the sale of its wholly owned subsidiary d-cyphaTrade Limited to the Australian Securities Exchange. d-cyphaTrade specializes in the design and marketing of Australian electricity derivatives traded on the ASX24 derivatives platform
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc